Overview
Tirzepatide extends the GLP-1 mechanism by adding GIP receptor activity, which the source article frames — together with semaglutide — as the best-evidenced and safest starting point in the peptide category.
peptide Metabolic & Weight Management
A dual agonist that activates both the GLP-1 and GIP receptors (GIP is a second incretin peptide released after meals). Described as a more powerful successor to semaglutide for appetite and weight reduction. FDA-approved (Mounjaro / Zepbound) and studied in tens of thousands of people.
Mounjaro · brand Zepbound · brand GLP-1/GIP dual agonist · other twincretin · other
Synonyms drive on-site search and are used to index ingested research papers and tweets to this page.
FDA-approved and extensively trialed. This page summarizes public information and commentary and is not medical advice.
No structured protocols recorded.
Tirzepatide extends the GLP-1 mechanism by adding GIP receptor activity, which the source article frames — together with semaglutide — as the best-evidenced and safest starting point in the peptide category.